Clinical Trials

449 results for 'Rochester, MN'

1. Gene Analysis for the Understanding of Barrett's Esophagus and Esophagus Cancer Jacksonville, FL Scottsdale and Phoenix, AZ Rochester, MN View Summary
   Close

   Gene Analysis for the Understanding of Barrett's Esophagus and Esophagus Cancer

   Location:

   Jacksonville, FL Scottsdale and Phoenix, AZ Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   This study is being done to advance the understanding of how esophagus cancer and Barrett's Esophagus develop as well as ways to treat these conditions. This will be done by analyzing blood and tissue to identify genes that may be involved in the development of esophagus cancer and Barrett's Esophagus.

   IRB Number:

   495-01

   • Print Summary
   • View study details
2. Establishment of Normal Ranges for Newly Developed Cardiovascular Assays Rochester, MN View Summary
   Close

   Establishment of Normal Ranges for Newly Developed Cardiovascular Assays

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   This research study is being done to determine levels of proteins that are normally present in the blood and urine of healthy individuals so as to compare to those levels in patients with heart disease.
   
   Normal blood and urine will be analyzed for levels of proteins and cardiac peptides which are affected by heart disease in the elderly. We are trying to determine if there are normal age-related changes when heart disease is not involved.

   IRB Number:

   718-05

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   If you are interested in participating in this study or would like additional information, please contact Sharon Sandberg or Dr. Fernando Martin at (507) 284-4838.

3. Familial Barrett's Esophagus Study Rochester, MN View Summary
   Close

   Familial Barrett's Esophagus Study

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   A group of doctors and scientists at the Mayo Clinic in Rochester, Minnesota, along with doctors from many other medical centers throughout the US, are working together to advance our understanding of Barrett's esophagus and esophagus cancer. The main aim of the present study is to collect blood for future testing. Once all the samples have been collected, tests to identify genes that may be involved in the development of Barrett's will be performed. A future goal is to learn if there is a genetic difference between those people who have Barrett's and develop cancer, and those who do not.

   IRB Number:

   1037-98

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   For more information or to participate in this research study, please contact Debra Geno at (507) 538-0367.

   Request Information Online
4. Drug Therapy for the Treatment of Upper Abdominal Pain Jacksonville, FL Scottsdale and Phoenix, AZ Rochester, MN View Summary
   Close

   Drug Therapy for the Treatment of Upper Abdominal Pain

   Location:

   Jacksonville, FL Scottsdale and Phoenix, AZ Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   This study is being done for people with upper abdominal discomfort or pain, early fullness after eating, nausea and/or upper abdominal bloating.
   
   We propose to investigate whether antidepressant medications are efficacious in functional dyspepsia. The prescription of antidepressants to treat functional dyspepsia is based on three propositions. First, antidepressants could reduce the severity of co-morbid psychological symptoms, especially anxiety and depression. Second, antidepressants have central analgesic actions. Thirdly, antidepressants have been shown to have local pharmacological actions on the gut, and may specifically alter gastric emptying and fundic relaxation based on preliminary data, but the relevance of such perturbations to treatment outcome is not established.

   NCT ID:

   NCT00275626

   IRB Number:

   2021-05

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   For more information or to participate in this research study, please call Vickie Silvernail, LPN at (507) 284-2812.

5. Quality of Life in Childhood Strabismus Rochester, MN View Summary
   Close

   Quality of Life in Childhood Strabismus

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   A brief questionnaire for the child and one for the parent explores the difficulties in dealing with Intermittent Exotropia, an out turning eye. The information will be helpful for assessing the full implact of this condition on children and their parents.

   IRB Number:

   06-005705

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Jan Sease, coordinator: 507-538-8119 or sease.jan@mayo.edu Sarah Hatt, orthoptist: 507-284-1913 or hatt.sarah@mayo.edu

6. DNA Repository for Addictions Rochester, MN View Summary
   Close

   DNA Repository for Addictions

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   This resource will be used to study variation in DNA possibly associated with developing addiction and response to treatment.

   IRB Number:

   2681-04

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Addictions Study Coordinator, 1-877-751-6444 (toll-free), psychaddiction@mayo.edu

7. Genetic Epidemiology Of Lung Cancer Rochester, MN View Summary
   Close

   Genetic Epidemiology Of Lung Cancer

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   The purpose of the study is to compare any inherited or genetic characteristics using blood or tissue specimens collected from individuals who have been diagnosed with lung cancer with the blood or tissue of their family members. The research study is funded by the National Cancer Institute and is part of a national research study being conducted by the Genetic Epidemiology of Lung Cancer Consortium (GELCC).

   IRB Number:

   07-007338

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Mariza de Andrade, Ph.D. Principal Investigator Phone: (507) 284-1032 Email: mandrade@mayo.edu

   Request Information Online
8. Mayo Clinic Sports Medicine Program and USA Hockey have recently developed a Catastrophic Injury Registry for Ice Hockey. Our goal is to capture information on all catastrophic and potentially catastrophic injuries at all levels of ice hockey so that we can follow-up with the injured parties, and appropriately catalogue their injury experience for USA Hockey. Rochester, MN View Summary
   Close

   Mayo Clinic Sports Medicine Program and USA Hockey have recently developed a Catastrophic Injury Registry for Ice Hockey. Our goal is to capture information on all catastrophic and potentially catastrophic injuries at all levels of ice hockey so that we can follow-up with the injured parties, and appropriately catalogue their injury experience for USA Hockey.

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   The purpose of this USA Hockey registry is to collect information on the prevalence of catastrophic injuries for both genders in youth, high school, junior, college, national program, adult amateur, minor league, and professional ice hockey in the United States. The goal is to design and maintain a comprehensive registry of catastrophic injuries in ice hockey that will be the primary source of catastrophic ice hockey injury data in the United States. The registry will provide data to support potential rule and equipment changes.

   IRB Number:

   08-002859

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   We have created an injury reporting phone line where a staff member can be contacted at 1-866-926-2563. We have also established a reporting email address at hockeyinjury@mayo.edu.

9. Rituximab in Progressive IgA Nephropathy Rochester, MN View Summary
   Close

   Rituximab in Progressive IgA Nephropathy

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Hypothesis: In patients with progressive IgA nephropathy an intravenous infusion of 1000 mg of rituximab on Day 1 and Day 15 and Days 168 and 182 is superior to conventional therapy in reducing 24 hour proteinuria, and slowing progression of chronic kidney disease. Rituximab doses for pediatric patients will be 375mg/m² of rituximab on Days 1 and Day 15 and Days 168 and 182. 2.0 OBJECTIVES 2.1 Primary Efficacy Endpoints: Percentage of patients in each group achieving complete or partial response as defined below: Complete Response: At 12 months 1. < 300 mg proteinuria/24 hours Pediatric Criteria: First morning void urine protein: creatinine ratio <0.3 2. No greater than a 10% reduction in baseline estimated GFR as determined by MDRD (4 point) formula Pediatric criteria: No greater than a 10% reduction in baseline estimated GFR as determined by Schwartz formula Partial Response: At 12 months 1) > 50% reduction in 24 hour proteinuria 2) No greater than a 25% reduction in baseline estimated GFR as determined by MDRD formula Pediatric criteria: No greater than a 25% reduction in baseline estimated GFR as determined by Schwartz formula No Response: At 12 months 1. A 50% reduction, unchanged or increasing proteinuria over baseline levels will be considered no response 2. A greater than a 30% reduction in baseline estimated GFR as determined by MDRD formula Pediatric criteria: A greater than a 25% reduction in baseline estimated GFR as determined by Schwartz formula 2.2 Primary Safety Endpoints: - Incidence of Infusion Related Reactions: Defined as the development of hypotension, generalized pruritus, chills/rigors, angioedema and/or bronchospasm. - Pulmonary Complications: Defined as a hypoxia, pulmonary infiltrates and/or acute respiratory failure - Incidence of Major Infections: Defined as the development of pneumonia, complicated UTI/Pyelonephritis, Sepsis, and Meningitis. - Development of Progressive Multifocal Leukoencephalopathy (PML) 2.3 Secondary Exploratory Efficacy Endpoints: A) For patients in Groups 1 & 2 consenting to a repeat kidney biopsy at 12 months, a secondary endpoint will include the percentage of patients in experiencing a 25% increase in cortical fibrosis. The response rate will be semi-quantified by the change in cortical fibrosis as measured by changes in Sirius Red staining of interstitial collagen. A patient will be considered a complete or partial response or no response according to the following criteria: Complete: Less than 10% rise in cortical fibrosis as measured by Sirius Red staining and digital image analysis Partial: Rising cortical fibrosis > 10% but less than 25% No Response: Greater than 25% rise in cortical fibrosis over baseline levels-(if patient consents to repeat kidney biopsy)

   NCT ID:

   NCT00498368

   IRB Number:

   07-001944

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Fernando C. Fervenza, M.D., Ph.D. 507-266-7961
                       Shirley A Jennison 507-255-0231
   
   
   

10. Primary Hyperoxaluria Mutation Genotyping Rochester, MN View Summary
    Close

    Primary Hyperoxaluria Mutation Genotyping

    Location:

    Rochester, MN

    Trial status:

    Open for Enrollment

    Why is this study being done?

    During your study visit, we will draw one tube, about two teaspoonfuls (1 to 1 ½ teaspoons for children), of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing. We will use the isolated DNA to try to identify the gene that is defective in Primary Hyperoxaluria by comparing it with the structure of genes in normal individuals, patients with Primary Hyperoxaluria, and family members of Primary Hyperoxaluria patients. In family members of primary hyperoxaluria patients, a 24 hour urine test may also be collected.

    NCT ID:

    NCT00589225

    IRB Number:

    434-03

    • Print Summary
    • View study details

    Who can I contact for additional information about this study?

    Rochester: Barbara Seide 507-255-0387
                        
    
    
    

1. 1
2. 2
3. 3
4. 4
5. 5
6. Next